Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study SuccessInvestors Business Daily • 11/28/22
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for ZuranoloneBusiness Wire • 11/22/22
CONTINUED INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Continues to Investigate Biogen Inc.'s Directors and Officers for Breach of Fiduciary Duties – BIIBBusiness Wire • 11/17/22
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The HelmInvestors Business Daily • 11/16/22
One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatmentsMarket Watch • 11/14/22
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And OthersInvestors Business Daily • 11/14/22
Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemabMarket Watch • 11/14/22